Form 4: Stoke Therapeutics Director Sells Shares Post-Vesting

Stoke Therapeutics Director Edward M. Kaye, MD, reported the acquisition of common stock from vested performance units and subsequent sales, primarily for tax obligations and a 10b5-1 plan.

Summary

• Edward M. Kaye, MD, a Director at Stoke Therapeutics, Inc. (STOK), reported changes in his beneficial ownership of common stock.
• On December 3, 2025, Dr. Kaye acquired 26,250 shares of common stock upon the vesting and settlement of performance stock units (PSUs).
• Following this acquisition, Dr. Kaye's beneficial ownership of non-derivative securities was 77,555 shares.
• On December 4, 2025, Dr. Kaye sold a total of 6,453 shares (5,222 shares at a weighted average price of $30.7635 and 1,231 shares at $31.3164) to satisfy tax withholding liabilities related to the vesting of restricted stock units.
• On December 5, 2025, Dr. Kaye sold a total of 8,548 shares (6,367 shares at a weighted average price of $31.3304, 1,681 shares at $31.1468, and 500 shares at $31.846).
• The sales on December 5, 2025, were executed pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2024.
• After all reported transactions, Dr. Kaye's beneficial ownership of common stock stands at 62,554 shares.
• The performance stock units (PSUs) converted to common stock on December 3, 2025, represented the remaining half of an award, with the first half having vested on December 3, 2024.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation vesting and pre-scheduled sales under a 10b5-1 plan. These are expected events and do not indicate a significant positive or negative shift in company fundamentals or insider sentiment.

Future Outlook

The filing indicates that the remaining half of the performance stock unit award vested on December 3, 2025, subject to the reporting person's continued service to the Issuer on that date.

Industry Context

This Form 4 filing details routine insider transactions for a director of a publicly traded biotechnology company. Such transactions, particularly those related to equity compensation vesting and tax obligations, are common across the industry and typically do not reflect a change in the company's fundamental business outlook or the insider's long-term confidence.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans for pre-scheduled stock sales is a standard practice among corporate insiders to avoid accusations of trading on material non-public information, aligning with best practices in corporate governance for executives and directors in the biotech sector and beyond.
• Sales to cover tax withholding liabilities upon the vesting of restricted stock units (RSUs) or performance stock units (PSUs) are also a common and expected occurrence for equity compensation recipients across all industries, including biotechnology, and are not indicative of a discretionary decision to reduce holdings.

Stakeholder Impact

• Shareholders: The transactions represent a minor reduction in a director's direct beneficial ownership, but the reasons (tax withholding, 10b5-1 plan) suggest no change in underlying sentiment. The overall impact on the company's stock price or long-term value is likely negligible.
• Employees: The vesting of performance stock units is a standard component of executive compensation, aligning employee incentives with company performance.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Sale, Director, Equity Compensation, Rule 10b5-1, Tax Withholding, Performance Stock Units, Restricted Stock Units